Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelly A King

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Lancet (London, England)|August 15, 2017
Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trialDaniel S Ory, Elizabeth A Ottinger, Nicole Yanjanin Farhat, et al.
Human Genetics|October 15, 2021
TUBB3 Arg262His causes a recognizable syndrome including CFEOM3, facial palsy, joint contractures, and early-onset peripheral neuropathyMary C Whitman, Brenda J Barry, Caroline D Robson, et al.
JAMA|March 18, 2024
Clinical, Biomarker, and Research Tests Among US Government Personnel and Their Family Members Involved in Anomalous Health IncidentsLeighton Chan, Mark Hallett, Chris K Zalewski, et al.
JAMA|March 18, 2024
Neuroimaging Findings in US Government Personnel and Their Family Members Involved in Anomalous Health IncidentsCarlo Pierpaoli, Amritha Nayak, Rakibul Hafiz, et al.
Nature Genetics|June 29, 2023
Noncoding variants alter GATA2 expression in rhombomere 4 motor neurons and cause dominant hereditary congenital facial paresisAlan P Tenney, Silvio Alessandro Di Gioia, Bryn D Webb, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Lancet (London, England)|August 15, 2017
Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trialDaniel S Ory, Elizabeth A Ottinger, Nicole Yanjanin Farhat, et al.
Human Genetics|October 15, 2021
TUBB3 Arg262His causes a recognizable syndrome including CFEOM3, facial palsy, joint contractures, and early-onset peripheral neuropathyMary C Whitman, Brenda J Barry, Caroline D Robson, et al.
JAMA|March 18, 2024
Clinical, Biomarker, and Research Tests Among US Government Personnel and Their Family Members Involved in Anomalous Health IncidentsLeighton Chan, Mark Hallett, Chris K Zalewski, et al.
JAMA|March 18, 2024
Neuroimaging Findings in US Government Personnel and Their Family Members Involved in Anomalous Health IncidentsCarlo Pierpaoli, Amritha Nayak, Rakibul Hafiz, et al.
Nature Genetics|June 29, 2023
Noncoding variants alter GATA2 expression in rhombomere 4 motor neurons and cause dominant hereditary congenital facial paresisAlan P Tenney, Silvio Alessandro Di Gioia, Bryn D Webb, et al.
Pageof 5